SCM
LYRA

Soleus Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Soleus Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,848
Closed -$2.32M – 93
2023
Q3 		$2.32M Hold
11,848
– – 0.21% 68
2023
Q2 		$2.43M Hold
11,848
– – 0.27% 68
2023
Q1 		$1.19M Hold
11,848
– – 0.12% 71
2022
Q4 		$1.86M Hold
11,848
– – 0.27% 61
2022
Q3 		$2.97M Hold
11,848
– – 0.4% 53
2022
Q2 		$3.35M Buy
+11,848
New +$3.23M 0.52% 53
2022
Q1 		– Sell
-200
Closed -$44K – 77
2021
Q4 		$44K Sell
200
-4,112
-95% -$1.32M ﹤0.01% 68
2021
Q3 		$1.97M Buy
4,312
+650
+18% +$246K 0.31% 59
2021
Q2 		$1.47M Sell
3,662
-5,854
-62% -$2.67M 0.23% 57
2021
Q1 		$5.51M Buy
9,516
+393
+4% +$246K 0.99% 19
2020
Q4 		$5.2M Buy
9,123
+6,910
+312% +$3.89M 0.69% 19
2020
Q3 		$1.24M Buy
2,213
+1,000
+82% +$622K 0.66% 39
2020
Q2 		$687K Buy
+1,213
New +$887K 0.39% 49

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Soleus Capital Management's LYRA Position: Q4 2023 in Review

Soleus Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2023, closing a stake of 11,848 shares — an estimated $2.32M sold.

Soleus Capital Management first reported a position in LYRA in Q2 2020 and held it in 13 quarters. The position peaked at $5.51M in Q1 2021. 60 funds tracked by Wall St. Rank hold LYRA as of Q4 2023.

  • Soleus Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 11,848 LYRA THERAPEUTICS INC shares in Q4 2023, an estimated $2.32M.
  • Soleus Capital Management first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 13 quarters.
  • Soleus Capital Management's LYRA THERAPEUTICS INC position peaked at $5.51M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.